Published in J Neurol on March 01, 2009
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J (2009) 1.84
Neuroborreliosis-associated cerebral vasculitis: long-term outcome and health-related quality of life. J Neurol (2013) 0.92
Cardioembolic but not other stroke subtypes predict mortality independent of stroke severity at presentation. Stroke Res Treat (2011) 0.90
Analysis of the Applicability of an Ankle-Foot Orthosis during Gait in Poststroke Patients. J Phys Ther Sci (2013) 0.86
The cost of first-ever stroke in Valle d'Aosta, Italy: linking clinical registries and administrative data. BMC Health Serv Res (2012) 0.80
Patient-level costs of major cardiovascular conditions: a review of the international literature. Clinicoecon Outcomes Res (2016) 0.77
Detection of occult atrial fibrillation in patients with embolic stroke of uncertain source: a work in progress. Front Physiol (2015) 0.75
Clinical and Economic Implications of AF Related Stroke. J Atr Fibrillation (2016) 0.75
Is HATCH score a reliable predictor of atrial fibrillation after cavotricuspid isthmus ablation for typical atrial flutter? Int J Cardiol Heart Vasc (2016) 0.75
[Clinical outcomes, health-related quality of life, and cost-effectiveness of a 6-month community- based lifestyle program for adults at increased cardiovascular risk in lower Austria]. Wien Med Wochenschr (2012) 0.75
FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J (1965) 38.57
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke (1993) 29.81
Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J (1957) 8.43
Cost of disorders of the brain in Europe. Eur J Neurol (2005) 6.41
Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev (2007) 5.93
Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke (2001) 4.87
Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med (2000) 4.81
Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke (1999) 3.80
Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med (1998) 3.79
Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med (2007) 3.06
Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence. Stroke (2000) 2.78
Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke (2001) 2.45
Assessment of scales of disability and handicap for stroke patients. Stroke (1991) 2.36
Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke (2006) 1.90
Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol (1989) 1.78
Alternative strategies for stroke care: cost-effectiveness and cost-utility analyses from a prospective randomized controlled trial. Stroke (2003) 1.74
Predictors of acute hospital costs for treatment of ischemic stroke in an academic center. Stroke (1999) 1.72
Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals. Neurology (2001) 1.57
Prediction of length of stay of first-ever ischemic stroke. Stroke (2002) 1.50
Predictors of pneumonia in acute stroke patients admitted to a neurological intensive care unit. J Neurol (2007) 1.40
Acute stroke care and rehabilitation: an analysis of the direct cost and its clinical and social determinants. The Copenhagen Stroke Study. Stroke (1997) 1.37
Cost-effectiveness of stroke unit care followed by early supported discharge. Stroke (2008) 1.25
Hospital-based study of the care and cost of acute ischemic stroke in Japan. Stroke (2003) 1.14
The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. Value Health (2007) 1.05
A randomised controlled comparison of alternative strategies in stroke care. Health Technol Assess (2005) 0.94
Cardioembolic stroke. Curr Atheroscler Rep (2006) 0.93
An analysis of the costs of ischemic stroke in an Italian stroke unit. Neurology (1999) 0.87
Brain embolism - Answers to practical questions. J Neurol (2003) 0.85
[Long-term disease-related costs 4 years after stroke or TIA in Germany]. Nervenarzt (2008) 0.83
The complications of cardioembolic stroke: lessons from the VISTA database. Cerebrovasc Dis (2008) 0.76
Cardiac evaluation of stroke patients. Neurology (1998) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 4.63
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol (2007) 2.99
Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci (2004) 2.84
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
The REM sleep behavior disorder screening questionnaire--a new diagnostic instrument. Mov Disord (2007) 2.64
Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke (2005) 2.29
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain (2005) 2.06
Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord (2003) 2.03
Hyperalgesia and functional sensory loss in restless legs syndrome. Pain (2013) 2.00
Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol (2005) 1.88
Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2008) 1.83
The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.78
Red flags for multiple system atrophy. Mov Disord (2008) 1.75
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Diffusion-weighted and perfusion MRI demonstrates parenchymal changes in complex partial status epilepticus. Brain (2005) 1.73
Projected numbers of people with movement disorders in the years 2030 and 2050. Mov Disord (2011) 1.70
Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem (2011) 1.64
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
Costs of illness and care in Parkinson's disease: an evaluation in six countries. Eur Neuropsychopharmacol (2011) 1.60
NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Exp Neurol (2008) 1.59
Gene expression profiling of Lewy body-bearing neurons in Parkinson's disease. Exp Neurol (2005) 1.58
IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells (2009) 1.57
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord (2005) 1.54
Intrathecal application of autologous bone marrow cell preparations in Parkinsonian syndromes. Mov Disord (2012) 1.50
Serum concentrations of s100b and NSE in migraine. Headache (2009) 1.48
Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (2006) 1.46
Memory for public events in patients with unilateral temporal lobe epilepsy. Epilepsy Behav (2010) 1.41
Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain (2002) 1.37
Role of MIF in inflammation and tumorigenesis. Oncology (2008) 1.36
Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A (2009) 1.35
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol (2007) 1.34
Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord (2008) 1.33
The future of Alzheimer's disease: the next 10 years. Prog Neurobiol (2011) 1.31
Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci (2003) 1.30
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem (2005) 1.27
Cytokines and epilepsy. Seizure (2011) 1.26
Contribution of obesity and abdominal fat mass to risk of stroke and transient ischemic attacks. Stroke (2008) 1.25
Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults. Nat Neurosci (2011) 1.24
Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol (2010) 1.24
Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain (2003) 1.24
Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat Disord (2007) 1.22
The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord (2014) 1.20
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol (2007) 1.20
Timecourse of health-related quality of life as determined 3, 6 and 12 months after stroke. Relationship to neurological deficit, disability and depression. J Neurol (2002) 1.20
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord (2010) 1.18
Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci (2007) 1.18
Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. Parkinsonism Relat Disord (2010) 1.16
Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem (2003) 1.15
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord (2009) 1.15
Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. Parkinsonism Relat Disord (2011) 1.15
Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord (2011) 1.14
Cost of epilepsy: a systematic review. Pharmacoeconomics (2008) 1.13
Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics (2005) 1.13
Rational therapeutic approaches to progressive supranuclear palsy. Brain (2010) 1.11
Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord (2005) 1.09
Assessing health-related quality of life in patients with restless legs syndrome. Sleep Med (2008) 1.07
Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord (2007) 1.07
Lack of differences of motorcortical excitability in the morning as compared to the evening in juvenile myoclonic epilepsy--a study using transcranial magnetic stimulation. Epilepsy Res (2007) 1.07
Comparative responsiveness of Parkinson's disease scales to change over time. Mov Disord (2009) 1.07
Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson's disease. A National Survey of German neurologists in private practice. J Neurol (2009) 1.06
Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study. J Geriatr Psychiatry Neurol (2009) 1.04
The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer (2009) 1.04
Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J Neurosci (2006) 1.04
Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol (2009) 1.04
Treatment of paroxysmal dyskinesias. Expert Opin Pharmacother (2010) 1.04
Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology (2012) 1.04
Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci Transl Med (2012) 1.02
Pathogenic and physiological autoantibodies in the central nervous system. Immunol Rev (2012) 1.01
Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Mov Disord (2003) 1.01
Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol (2012) 1.00
Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord (2004) 1.00
Health-related quality of life in patients with Gilles de la Tourette's syndrome. Mov Disord (2010) 0.98
Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neurosci Lett (2008) 0.98
The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings. J Alzheimers Dis (2013) 0.98
Intravenous initiation and maintenance of ketogenic diet: proof of concept in super-refractory status epilepticus. Seizure (2013) 0.98
Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies. Exp Neurol (2009) 0.98
Costs of Parkinson's disease in eastern Europe: a Czech cohort study. Parkinsonism Relat Disord (2009) 0.97
Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev (2008) 0.97
Health-related quality of life and its determinants in Parkinson's disease: results of an Italian cohort study. Parkinsonism Relat Disord (2011) 0.96
Bee venom and its component apamin as neuroprotective agents in a Parkinson disease mouse model. PLoS One (2013) 0.96
Re-admission to Level 2 unit after hip-fracture surgery - Risk factors, reasons and outcome. Injury (2013) 0.96
Language lateralization in children using functional transcranial Doppler sonography. Dev Med Child Neurol (2009) 0.95
Etiology and site of temporal lobe epilepsy influence postictal cytokine release. Epilepsy Res (2009) 0.95
Systemic administration of neuregulin-1β1 protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem (2011) 0.94